While KRAS mutation has proven to be predictive of the resistance to epidermal growth factor receptor (EGFR)-inhibiting therapies [3,4], the prognostic value of KRAS mutation in CRC remains unclear. This evidence concerns the gene EGFR and colorectal carcinoma.